CD14+HLA-DRlow/− cells are increased in several solid tumors, including metastatic melanoma,27 hepatocellular carcinoma,28 squamous cell carcinoma of the head and neck,29 glioblastoma,30 prostate cancer31 and chronic lymphocytic leukemia.32, 33 Our previous study observed14 that the numbers of CD14+HLA-DRlow/− monocytes increased in relapsed B-cell NHL patients. This evidence concerns the gene CD14 and hepatocellular carcinoma.